Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

Author:

Iwata Hiroji1,Tamura Kenji2,Doi Toshihiko3,Tsurutani Junji4,Modi Shanu5,Park Haeseong6,Krop Ian E.7,Sagara Yasuaki8,Redfern Charles H.9,Murthy Rashmi Krishna10,Redman Rebecca A.11,Shitara Kohei12,Fujisaki Yoshihiko13,Sugihara Masahiro14,Zhang Lin15,Shahidi Javad15,Yver Antoine15,Takahashi Shunji16

Affiliation:

1. Aichi Cancer Center, Nagoya, Japan;

2. National Cancer Center Hospital, Tokyo, Japan;

3. National Cancer Center Hospital East, Kashiwa, Japan;

4. Kindai University Faculty of Medicine, Osaka, Japan;

5. Memorial Sloan Kettering Cancer Center, New York City, NY;

6. Washington University School of Medicine, St. Louis, MO;

7. Dana-Farber Cancer Institute, Boston, MA;

8. Social medical corporation Hakuaikai Sagara Hospital, Kagoshima City, Japan;

9. Sharp Healthcare, San Diego, CA;

10. University of Texas MD Anderson Cancer Center, Houston, TX;

11. The University of Louisville, Louisville, KY;

12. National Cancer Center Hospital East, Chiba, Japan;

13. Daiichi Sankyo Co., Ltd., Tokyo, Japan;

14. Daiichi Sankyo, Co., Ltd, Tokyo, Japan;

15. Daiichi Sankyo, Inc., Basking Ridge, NJ;

16. The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo, Japan;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3